Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
REVERSIBLE METABOLISM OF CLOZAPINE AND CLOZAPINE N-OXIDE IN SCHIZOPHRENIC-PATIENTS
Autore:
CHANG WH; LIN SK; LANE HY; WEI FC; HU WH; LAM YWF; JANN MW;
Indirizzi:
TAIPEI CITY PSYCHIAT CTR,LAB BIOL PSYCHIAT,309 SUNG TE RD TAIPEI 10510 TAIWAN HUNG CHI PSYCHIAT HOSP TAIPEI TAIWAN UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL SAN ANTONIO TX 00000 MERCER UNIV,SO SCH PHARM,DEPT PHARMACEUT SCI ATLANTA GA 00000 MERCER UNIV,SO SCH PHARM,DEPT PHARM PRACTICE ATLANTA GA 00000
Titolo Testata:
Progress in neuro-psychopharmacology & biological psychiatry
fascicolo: 5, volume: 22, anno: 1998,
pagine: 723 - 739
SICI:
0278-5846(1998)22:5<723:RMOCAC>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERFORMANCE LIQUID-CHROMATOGRAPHY; CLINICAL-RESPONSE; SERUM LEVELS; ULTRAVIOLET DETECTION; REDUCED HALOPERIDOL; MAJOR METABOLITES; PLASMA-LEVELS; PHARMACOKINETICS; DESMETHYLCLOZAPINE; NORCLOZAPINE;
Keywords:
CLOZAPINE; CLOZAPINE N-OXIDE; DESMETHYLCLOZAPINE; PLASMA CONCENTRATIONS; REVERSIBLE METABOLISM;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
32
Recensione:
Indirizzi per estratti:
Citazione:
W.H. Chang et al., "REVERSIBLE METABOLISM OF CLOZAPINE AND CLOZAPINE N-OXIDE IN SCHIZOPHRENIC-PATIENTS", Progress in neuro-psychopharmacology & biological psychiatry, 22(5), 1998, pp. 723-739

Abstract

1. To characterize the interconversion process between clozapine and its metabolite clozapine N-oxide (CNO), eight healthy male schizophrenics were administered a single dose of clozapine or CNO in a randomized crossover manner. 2. Using a general pharmacokinetic model for the interconversion process, the mean total clearances of clozapine and CNOwere 28.45 L/hr and 45.30 L/hr, respectively. These values were similar to the values obtained by the usual model-independent method of pharmacokinetic analysis. 3. When administered clozapine, mean CNO plasmaconcentrations of 17.7 +/- 16.4 ng/ml were slightly lower than the other clozapine metabolite-desmethylclozapine (DCLOZ) plasma levels of 24.4 +/- 8.6 ng/ml at the 12 hour time point. When CNO was administered, plasma concentrations at the 12 hour time point of clozapine were twice the amount. of CNO (28.1 +/- 8.9 ng/ml vs 14.4 +/- 8.8 ng/ml). 4. DCLOZ plasma concentrations were detected in all patients upon clozapine administration. Upon CNO administration, only one patient had detectable plasma DCLOZ levels. 5. The interconversion process of clozapineand CNO could partially account for the wide interpatient variabilityreported for clozapine plasma concentrations in schizophrenic patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 16:01:53